Literature DB >> 26911612

Osteoporosis treatment: complexities and challenges.

R A Adler1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26911612     DOI： 10.1007/s40618-016-0437-5

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  2 in total

Review 1.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

2.  Undertreatment of osteoporosis and the role of gastrointestinal events among elderly osteoporotic women with Medicare Part D drug coverage.

Authors:  Ethel S Siris; Jingbo Yu; Katalin Bognar; Mitch DeKoven; Anshu Shrestha; John A Romley; Ankita Modi
Journal:  Clin Interv Aging       Date:  2015-11-05       Impact factor: 4.458
  2 in total
  8 in total

1.  The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.

Authors:  C Cipriani; J Pepe; F Bertoldo; G Bianchi; F P Cantatore; A Corrado; M Di Stefano; B Frediani; D Gatti; A Giustina; T Porcelli; G Isaia; M Rossini; L Nieddu; S Minisola; G Girasole; M Pedrazzoni
Journal:  J Endocrinol Invest       Date:  2017-09-27       Impact factor: 4.256

Review 2.  New anabolic therapies for osteoporosis.

Authors:  Salvatore Minisola; Cristiana Cipriani; Marco Occhiuto; Jessica Pepe
Journal:  Intern Emerg Med       Date:  2017-08-05       Impact factor: 3.397

3.  Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.

Authors:  S Migliaccio; D Francomano; E Romagnoli; C Marocco; R Fornari; G Resmini; A Buffa; G Di Pietro; S Corvaglia; F Gimigliano; A Moretti; A de Sire; N Malavolta; A Lenzi; E A Greco; G Iolascon
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

4.  The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.

Authors:  J Pepe; C Cipriani; F P Cantatore; A Fabbri; E Pola; V Vinicola; O Raimo; F Biamonte; R Pascone; C Ferrara; S Minisola
Journal:  J Endocrinol Invest       Date:  2017-02-25       Impact factor: 4.256

Review 5.  Adverse effects of media reports on the treatment of osteoporosis.

Authors:  Cristiana Cipriani; Jessica Pepe; Salvatore Minisola; E Michael Lewiecki
Journal:  J Endocrinol Invest       Date:  2018-05-14       Impact factor: 4.256

6.  Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.

Authors:  E Cairoli; S Palmieri; G Goggi; L Roggero; M Arosio; I Chiodini; C Eller-Vainicher
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

7.  FGD5-AS1 facilitates the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells via targeting the miR-506-3p/BMP7 axis.

Authors:  Jun Li; Xingbiao Wu; Yaohua Shi; Hong Zhao
Journal:  J Orthop Surg Res       Date:  2021-11-12       Impact factor: 2.359

Review 8.  Oxidative stress as a possible pathogenic cofactor of post-menopausal osteoporosis: Existing evidence in support of the axis oestrogen deficiency-redox imbalance-bone loss.

Authors:  Gloria Bonaccorsi; Isabella Piva; Pantaleo Greco; Carlo Cervellati
Journal:  Indian J Med Res       Date:  2018-04       Impact factor: 2.375
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.